Ganeden Biotech’s patented probiotic ingredient is now available in six of the seven continents.

Ganeden Biotech has announced that probiotic ingredient GanedenBC30 (Bacillus coagulans GBI-30, 6086) which bagged several international regulatory approvals is now being shipped to six of the seven continents. This means that its probiotic ingredient  known for its digestive and immune benefits are now available globally for food and beverage fortification.

The company is engaged in probiotic research and product development with an extensive library of published studies and more than 100 patents for probiotic technologies in the food, beverage, animal health, and now personal care ingredients markets. It is known for its GanedenBC30), a patented, FDA GRAS which is a highly stable probiotic ingredient. Its newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging.

The global market of probiotic ingredients, supplements, and foods is expected to reach nearly $27.1 billion in 2013 and register a compound annual growth rate of 6.2 per cent over the next five years to reach $36.7 billion in 2018, according to Wellesley, MA- based technology markets research firm BCC Research.

“The international probiotic market is growing at a breakneck pace, and the interest in GanedenBC30 is astounding. Achieving a global footprint for GanedenBC30 has been an ongoing objective for the company which is engaged in ensuring that its product studies that support claims for safety and efficacy are published in peer reviewed journals,”  said Mike Bush, senior vice-president at Ganeden Biotech.

Each country has a set of regulatory guidelines for food and beverage ingredients. The overall process is very thorough and can take anywhere from weeks to years. Ganeden Biotech has received regulatory approvals for GanedenBC30 in over sixty countries throughout North America, Asia, Europe, South America, Africa, and Oceania; which has resulted in six international product launches in just the first quarter of 2014.

By the end of the year Ganeden expects to receive approvals in six additional countries; with many more to come in 2015. For more information on the availability of GanedenBC30, please contact Ganeden Biotech.